
    
      This post-market approval study (PAS) is required by the FDA as a condition of approval for
      the Lutonix drug coated balloon catheter. It is intended to demonstrate safety and assess the
      clinical use and outcomes of the LUTONIX Catheter in dysfunctional arteriovenous fistulae
      (AVF) in a heterogeneous patient population in real world clinical practice.
    
  